BioSpace News Archive

GreenLight Biosciences Inc., an RNA-focused biotech, and Environmental Impact Acquisition Corp. announced an expansion of its PIPE financing to an aggregate $124 million in gross proceeds.

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced new AI-enabled innovations in MR imaging launching at the Radiological Society of North America (RSNA) annual meeting (November 23 – December 2, Chicago, USA).

The US Food and Drug Administration (FDA) granted Breakthrough Device Designation for Hagar’s GWave, the world’s first non-invasive continuous glucose monitoring technology that uses radiofrequency (RF) waves to measure glucose levels in the blood.

Tauriga Sciences, Inc., a New York based diversified Life Sciences Company, announced the results of its Special Meeting of stockholders held at 9:00am EST on November 22, 2021.

Median Technologies (Paris:ALMDT) (ALMDT:PA) announces new outstanding performance of its lung cancer screening (LCS) CADx to characterize malignant vs. benign lung nodules.

Onxeo S.A. announced the appointment of Bryan Giraudo as independent member of the Board of Directors, replacing Thomas Hofstaetter after three mandates.

Patterson Companies announced that it will hold its fiscal 2022 second-quarter conference call on Wednesday, December 1, 2021 at 7:30 a.m. CT.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of the management team will participate virtually in the 4th Annual Evercore ISI HealthCONx Conference.

Amyris, Inc. (Nasdaq: AMRS) (“Amyris”), a leading synthetic biotechnology company accelerating the world to sustainable consumption through its Lab-to-Market™ operating platform, today announced that management will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference.

According to the latest research by Fact MR, the sales of testosterone nasal gels market will experience substantial growth with a CAGR of 3% during the forecast period 2021-2031.